This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Management

Authoring team

Management is similar to that of a deep venous thrombosis, including: (1)

  • anticoagulation to prevent the propagation of thrombus and to encourage clot lysis. Acute treatment with parenteral anticoagulation (low molecular weight heparin, fondaparinux, intravenous/subcutaneous unfractionated heparin) is recommended. Low molecular weight heparin or fondaparinux are preferred. Rivaroxaban and apixaban can also be used.
  • anticoagulant therapy is recommended in preference to thrombolysis and should be continued for three months to six months. (2)
  • investigation and treatment of predisposing factors

In a few patients, surgical excision of the first rib may be helpful. Investigations are underway to determine if compression therapy may help prevent or treat post-thrombotic syndrome. (3)

Reference

  1. Guyatt GH et al; Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):7S-47S.
  2. Mustafa J, Asher I, Sthoeger Z; Upper Extremity Deep Vein Thrombosis: Symptoms, Diagnosis, and Treatment. Isr Med Assoc J. 2018 Jan;20(1):53-57.
  3. Ramadan SM, Kasfiki EV, Kelly C, Ali I. Primary upper extremity deep vein thrombosis (effort thrombosis). Acute Med. 2021;20(2):151-153

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2026 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.